Junning Cao

2.0k total citations
90 papers, 907 citations indexed

About

Junning Cao is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Junning Cao has authored 90 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pathology and Forensic Medicine, 53 papers in Oncology and 18 papers in Genetics. Recurrent topics in Junning Cao's work include Lymphoma Diagnosis and Treatment (53 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (15 papers). Junning Cao is often cited by papers focused on Lymphoma Diagnosis and Treatment (53 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (15 papers). Junning Cao collaborates with scholars based in China, United States and South Korea. Junning Cao's co-authors include Xiaonan Hong, Dongmei Ji, Fangyuan Chen, Shanhua Zou, Junmin Li, Jianmin Wang, Weiguo Su, Zhiyu Chen, Songhua Fan and Jun Zhu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Junning Cao

81 papers receiving 892 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junning Cao China	16	553	381	213	141	140	90	907
Masahiro Yokoyama Japan	15	461 0.8×	575 1.5×	124 0.6×	128 0.9×	185 1.3×	61	1.0k
Haiyi Guo China	12	743 1.3×	447 1.2×	429 2.0×	97 0.7×	116 0.8×	28	1.3k
Martin‐Leo Hansmann Germany	18	530 1.0×	819 2.1×	182 0.9×	99 0.7×	352 2.5×	27	1.3k
Tong-Yu Lin China	22	586 1.1×	461 1.2×	163 0.8×	63 0.4×	237 1.7×	47	1.3k
Sang Eun Yoon South Korea	16	537 1.0×	475 1.2×	99 0.5×	66 0.5×	259 1.9×	102	949
H.‐G. Mergenthaler Germany	12	543 1.0×	206 0.5×	212 1.0×	134 1.0×	68 0.5×	33	903
Hui-Qiang Huang China	22	819 1.5×	740 1.9×	139 0.7×	90 0.6×	451 3.2×	51	1.4k
Bin Meng China	18	334 0.6×	151 0.4×	186 0.9×	53 0.4×	136 1.0×	62	814
Xiaonan Hong China	20	1.0k 1.9×	930 2.4×	416 2.0×	99 0.7×	212 1.5×	71	1.7k
He Huang China	19	480 0.9×	207 0.5×	159 0.7×	217 1.5×	192 1.4×	78	1.4k

Countries citing papers authored by Junning Cao

Since Specialization

Citations

This map shows the geographic impact of Junning Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junning Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junning Cao more than expected).

Fields of papers citing papers by Junning Cao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junning Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junning Cao. The network helps show where Junning Cao may publish in the future.

Co-authorship network of co-authors of Junning Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Junning Cao. A scholar is included among the top collaborators of Junning Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junning Cao. Junning Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ji, Dongmei, Shufang Wang, Dibo Hou, et al.. (2025). Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial. Clinical Drug Investigation. 45(11). 889–899.

Song, Zheng, Ying Cheng, Haiyan Yang, et al.. (2024). Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. Blood. 144(Supplement 1). 986–986. 1 indexed citations

Chen, Guangliang, Qunling Zhang, Ran Li, et al.. (2024). Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study. Cancer Medicine. 13(16). e70142–e70142. 3 indexed citations

Wu, Yonghe, Baohua Yu, Qunling Zhang, et al.. (2024). PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis. Blood Research. 59(1). 36–36. 2 indexed citations

Luo, Zhiguo, Xin Liu, Xiaoying Zhang, et al.. (2023). 1208MO A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary. Annals of Oncology. 34. S712–S712. 2 indexed citations

Cao, Junning, Hongqian Guo, Dongmei Ji, et al.. (2023). Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial. The Oncologist. 28(12). e1259–e1267. 4 indexed citations

Bachy, Emmanuel, Kerry J. Savage, Huiqiang Huang, et al.. (2022). Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.. Journal of Clinical Oncology. 40(16_suppl). 7552–7552. 6 indexed citations

Gu, Bingxin, Jiyi Hu, Lin Kong, et al.. (2021). Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma. Annals of Nuclear Medicine. 35(7). 834–842. 9 indexed citations

Zhang, Yao, Yizhen Liu, Zuguang Xia, et al.. (2021). Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma. Annals of Translational Medicine. 9(14). 1178–1178. 4 indexed citations

10.

Wang, Leiping, et al.. (2020). PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR. Molecular Medicine Reports. 21(5). 2209–2219. 10 indexed citations

11.

Ji, Dongmei, Jian Zhang, Junning Cao, et al.. (2020). A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy. Medicine. 99(44). e22886–e22886. 3 indexed citations

12.

Han, Jun, et al.. (2020). 174P A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study. Annals of Oncology. 31. S1307–S1307. 13 indexed citations

13.

Liu, Yizhen, Yumei Liu, Ping Zhao, et al.. (2020). <p>Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma</p>. Cancer Management and Research. Volume 12. 5041–5048. 2 indexed citations

14.

Song, Yuqin, Jianqiu Wu, Xinchuan Chen, et al.. (2019). A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Clinical Cancer Research. 25(24). 7363–7369. 109 indexed citations

15.

Xu, Rui‐Hua, Jin Li, Yuxian Bai, et al.. (2017). Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology & Oncology. 10(1). 63 indexed citations

16.

Wei, Zheng, Shanhua Zou, Feng Li, et al.. (2014). HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China. Medical Oncology. 31(3). 845–845. 17 indexed citations

17.

Zhang, Jian, Junning Cao, Jin Li, et al.. (2014). A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. Journal of Hematology & Oncology. 7(1). 22–22. 31 indexed citations

18.

Kim, Seok Jin, Hyun Ae Jung, Shih‐Sung Chuang, et al.. (2013). Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group. Journal of Hematology & Oncology. 6(1). 86–86. 55 indexed citations

19.

Cao, Bing, Xiaoyan Zhou, Dongmei Ji, et al.. (2012). Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab. Oncology Letters. 4(3). 541–545. 3 indexed citations

20.

Zhang, Jian, et al.. (2012). Rituximab in treatment of primary gastric diffuse large B-cell lymphoma. Leukemia & lymphoma. 53(11). 2175–2181. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact